FDA Grants Accelerated Approval for OTOF Gene Therapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.

  • By

  • Kathryn Wighton

  • April 23, 2026

  • 3 min

Share

  • 1

    The FDA has granted accelerated approval for lunsotogene parvec-cwha to treat severe-to-profound sensorineural hearing loss due to OTOF gene variants.

  • 2

    The therapy uses an adeno-associated virus vector to deliver a functional OTOF gene copy to cochlear hair cells, aiming to restore hearing.

  • 3

    In the Phase 1/2 CHORD trial, 16 of 20 patients improved to 70 decibels or better at 24 weeks, indicating significant hearing restoration.

  • 4

    The therapy is not recommended for patients with prior cochlear implants or those without accessible inner ear access.

  • 5

    Adverse events included otitis media and dizziness, with surgical risks such as meningitis and facial nerve complications.

Original Source(s)

FDA Grants Accelerated Approval for OTOF Gene Therapy

  • by Kathryn Wighton

  • April 23, 2026

Related Content

JAMA Otolaryngology–Head & Neck Surgery —The Year in Review, 2025

A Smarter Path for Dizziness: When and Why to Refer for Vestibular Therapy

Dizziness is one of the most common yet complex complaints encountered across primary care, neurology, otolaryngology, and cardiology. It can present as vertigo, imbalance, or nonspecific lightheadedness. It can leave both patients and physicians searching for clear answers.

  • by

  • May 18, 2026

  • 6 min
Medical Oddities: Ancient Practice Calms Modern BP

Ancient workouts, anxious ears, tea gains, limb regrowth, and furry tongues collide.